Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1715
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2626
    +0.0004 (+0.03%)
     
  • Bitcoin GBP

    55,470.23
    -597.98 (-1.07%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc
("Summit" or the "Company")

EXERCISE OF SHARE OPTIONS

Oxford, UK, 10 April 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that, following the exercise of employee share options, the Company has issued 16,667 new ordinary shares of 1p each (the "New Ordinary Shares").

Application has been made for the admission to trading on AIM of the New Ordinary Shares, which will rank pari passu with the Company`s existing ordinary shares, and admission is expected to occur on or around 18 April 2017.

ADVERTISEMENT

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 61,908,233. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA`s Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

- END -

For more information, please contact:

Summit Therapeutics
Richard Pye (UK office)
Erik Ostrowski (US office)



Tel: +44 (0)1235 443 951
+1 617 294 6607

Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson





Tel: +44 (0)20 7213 0880




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via GlobeNewswire

HUG#2095254